Organic electroluminescent materials and devices are disclosed. The organic electroluminescent materials are novel benzodithiophene or its analogous structure compounds, which can be used as charge transporting materials, hole injection materials, or the like in an electroluminescent device. These novel compounds can offer excellent performance compared with existing materials, for example, to further improve the voltage, efficiency and/or lifetime of the OLEDs.

Organic electroluminescent materials and devices are disclosed. The organic electroluminescent materials are novel benzodithiophene or its analogous structure compounds, which can be used as charge transporting materials, hole injection materials, or the like in an electroluminescent device. These novel compounds can offer excellent performance compared with existing materials, for example, to further improve the voltage, efficiency and/or lifetime of the OLEDs.

Disclosed are a compound represented by Chemical Formula 1A or 1B, an organic thin film including the same, a thin film transistor, and an electronic device.

##STR00001##

In Chemical Formulae 1A and 1B, X.sup.1, X.sup.2, R.sup.1 to R.sup.4, and n1 are the same as described in the detailed description.

Disclosed are a compound represented by Chemical Formula 1A or 1B, an organic thin film including the same, a thin film transistor, and an electronic device.

##STR00001##

In Chemical Formulae 1A and 1B, X.sup.1, X.sup.2, R.sup.1 to R.sup.4, and n1 are the same as described in the detailed description.

The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances. ##STR00001##

The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances. ##STR00001##

In an embodiment is provided a method of making a photo-absorbing composition that includes forming a donor-acceptor small molecule (DASM) by bonding an electron donor portion to an electron acceptor portion; and bonding the DASM to a nanographene structure using a Stille coupling reaction, a Suzuki cross-coupling reaction, or a CH activation cross-coupling reaction. In another embodiment is provided films that include a photo-absorbing composition.

In an embodiment is provided a method of making a photo-absorbing composition that includes forming a donor-acceptor small molecule (DASM) by bonding an electron donor portion to an electron acceptor portion; and bonding the DASM to a nanographene structure using a Stille coupling reaction, a Suzuki cross-coupling reaction, or a CH activation cross-coupling reaction. In another embodiment is provided films that include a photo-absorbing composition.

The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.

The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.